Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Frost (Houston, United States of America), C. Zhao (South San Francisco, United States of America), H. Farber (Boston, United States of America), R. Benza (Pittsburgh, United States of America), M. Selej (South San Francisco, United States of America), G. Elliott (Murray, United States of America). Smoking history and pulmonary arterial hypertension (PAH) onset and clinical outcomes (REVEAL). 3552

Member's Comments

No comment yet.

Related content which might interest you: Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Age, risk and outcomes in idiopathic pulmonary arterial hypertension Source: Eur Respir J, 51 (5) 1800629; 10.1183/13993003.00629-2018 Year: 2018 Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Risk stratification in pulmonary arterial hypertension (PAH) Source: International Congress 2018 – New trends in the management of pulmonary hypertension Year: 2018 Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Survival in pulmonary hypertension in Spain: insights from the Spanish registry}, Source: Eur Respir J 2012; 40: 596-603 Year: 2012 An international survey of current pulmonary arterial hypertension (PAH) management Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Co-morbidities and pulmonary arterial hypertension (PAH) in COPD patients Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Epidemiological and Clinical aspects of pulmonary arterial hypertension (PAH) Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018 Comparison of activities of daily living in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases Year: 2016 EmPHasis-10 is associated with clinical outcome measures in pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Bosentan delays time to clinical worsening (TTCW) and improves haemodynamics in who class II pulmonary arterial hypertension (PAH) patients: EARLY study results Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Cambridge pulmonary hypertension outcomes review (CAMPHOR) utility assessment in pulmonary hypertension (PH) patients Source: Annual Congress 2007 - Pulmonary hypertension in the clinic Year: 2007 The study of risk in pulmonary arterial hypertension Source: Eur Respir Rev 2012 21:234-238 Year: 2012 The French registry of pulmonary arterial hypertension in children: characteristics at diagnosis Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016